Quick Answer
Dermata Therapeutics, Inc. reported Cash and Equivalents of $7.52 million for fiscal year 2025.
Dermata Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $7.52M | +137.9% |
| 2024 | $3.16M | -49.3% |
| 2022 | $6.24M | -42.2% |
| 2021 | $10.80M | +1936.0% |
| 2020 | $530.4K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.66M | — | -28.0% |
| June 30, 2025 | $6.48M | — | -33.3% |
| March 31, 2025 | $9.72M | — | +207.4% |
| December 31, 2024 | $3.16M | — | -52.3% |
| September 30, 2023 | $6.63M | -17.8% | -21.4% |
| June 30, 2023 | $8.44M | -20.6% | -3.7% |
| March 31, 2023 | $8.77M | +7.0% | +40.5% |
| December 31, 2022 | $6.24M | -42.2% | -22.6% |
- Dermata Therapeutics, Inc. showed an increase of +137.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Dermata Therapeutics, Inc.’s cash and equivalents has grown by 1318.2% (from $530.4 thousand to $7.52 million).
- The most recent figure is from Dermata Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: